Return-Path: <1axbp27csef0kjs69cor3wd1gf3jr8wzfmp0gi-alvarochf=traceseis.com@bf04x.hubspotemail.net> Delivered-To: alvarochf@traceseis.com Received: from cs510.bluehost.com by cs510.bluehost.com with LMTP id wJjnBRzChGmhnAQAWiBQxw (envelope-from <1axbp27csef0kjs69cor3wd1gf3jr8wzfmp0gi-alvarochf=traceseis.com@bf04x.hubspotemail.net>) for ; Thu, 05 Feb 2026 09:15:24 -0700 Return-path: <1axbp27csef0kjs69cor3wd1gf3jr8wzfmp0gi-alvarochf=traceseis.com@bf04x.hubspotemail.net> Envelope-to: alvarochf@traceseis.com Delivery-date: Thu, 05 Feb 2026 09:15:24 -0700 Received: from bd77ghd.bf04x.hubspotemail.net ([143.244.90.159]:40367) by cs510.bluehost.com with esmtps (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_128_GCM_SHA256 (Exim 4.98.2) (envelope-from <1axbp27csef0kjs69cor3wd1gf3jr8wzfmp0gi-alvarochf=traceseis.com@bf04x.hubspotemail.net>) id 1vo20p-00000001TQy-3x9n for alvarochf@traceseis.com; Thu, 05 Feb 2026 09:15:24 -0700 Received: by 172.16.84.104 with SMTP id a0h5nnp5ez4m1s9lr6wp37cma7pwul83dx2pyqn3ij; Thu, 5 Feb 2026 16:15:13 GMT DKIM-Signature: v=1; s=hs1; d=bf04x.hubspotemail.net; i=@bf04x.hubspotemail.net; h=sender:from:from:reply-to:to:to:cc:cc:subject:subject:list-unsubscribe:form-sub:feedback-id:list-unsubscribe-post; a=rsa-sha256; c=relaxed/relaxed; bh=7Qgj4v/vC73PMfF1Lsp+v9Yr8YPZeEpz6k46f5Ts888=; b=v3VpBUinw/uHDlSvXwNzsox/ZAFiYpUUfJn9wgd5xLZ1QWrwWzLwzIwDzzlxqD JuBartDa31OrVIRqv3T2IEEsVlJFNe92zAZHwyQSbBLvfwvfe3KhtRXA+IhzkCq TPVygP6Guqu1Y26BjV9vIBwk8gnN4a4lSURe1H3JCq20Ka0QMqc25FG3EfuXJ7J rS5AmPVIiPj8PnOQ1Ypao0jfSiY42nXkwIWvYRfSy3mR6URv3oww8tGd1XD8a4c c+mLZXOc/T5wpuzUiJcPGn8oc8MVnj6M7wRO7xr6D1TUrjTyooIvzOFd2AEF1zv rKFsF7YVwPIbdzWSvK2Pt5gs2XyQ==; q=dns/txt; t=1770308113; x=1770570913; DKIM-Signature: v=1; s=hs1; d=bf04x.hs-send.com; i=@bf04x.hs-send.com; h=sender:from:from:reply-to:to:to:cc:cc:subject:subject:list-unsubscribe:form-sub:feedback-id:list-unsubscribe-post; a=rsa-sha256; c=relaxed/relaxed; bh=7Qgj4v/vC73PMfF1Lsp+v9Yr8YPZeEpz6k46f5Ts888=; b=AaiVyGHMY4DrDoekD4/TF9Cst46yByDs0M6DMCpjQOMatLuzbEPH8es0CUiT0s GwS+8nPsK5Mj2spt1FigfPuW2EvnPm+xbPS0ij78VHDrnOUvJyvTlrnMny+L/ok m6wIgMyJIq4OeJYvzdOqLc14epwBHDAfbQcRye1ey+t0BlR4CAqYtCnDPXVobk1 44sFV+xFJ60TjMUjFgDWzrfA1qOhFtDtYqZ2gdM3hAmAdCShYTPK9ld9u6NtBeu uYQstNCe/93vpLQImkk7Acufm03ErOxbnoAfXn6zVWha2PXxu64gi01bfc8QQ5Z oLGL/acXsl541P7rA4PaFx0cEkKw==; q=dns/txt; t=1770308113; x=1770570913; X-HS-Cid: 1axfi4wx5jbynqbxq1j2ewyni60kjs4oszkngy List-Unsubscribe: , Date: Thu, 5 Feb 2026 11:15:13 -0500 From: Daniel Nguyen Reply-To: daniel@akadeum.com To: alvarochf@traceseis.com Message-ID: <1770308112430.221eaa3f-a213-4258-9bce-0d3802909b78@bf04x.hubspotemail.net> Subject: =?utf-8?Q?New_App_Note:_Microbubbles_Integrate_with_th?= =?utf-8?Q?e_Cytiva_Sepax=E2=84=A2_C-Pro_Cell_Processing_System?= MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_Part_1767517_1243901796.1770308112951" X-Report-Abuse-To: abuse@hubspot.com (see https://policy.hubspot.com/abuse-complaints) List-Unsubscribe-Post: List-Unsubscribe=One-Click Feedback-ID: aedfxo7:aigxny2o:airvv:HubSpot ------=_Part_1767517_1243901796.1770308112951 Content-Type: text/plain; charset=utf-8 Content-Transfer-Encoding: quoted-printable Higher recovery, favorable phenotype, and increased cytotoxicity in a close= d Sepax workflow Hi Alvaro, We=E2=80=99ve released a new application note evaluating a fully closed T c= ell isolation workflow integrating Akadeum microbubbles with the Cytiva Sep= ax=E2=84=A2 C-Pro Cell Processing System in a CD19 CAR-T model. This application note accompanies the data shared in our recent webinar (ht= tps://cDHpZ04.na1.hubspotlinks.com/Ctc/T+113/cDHpZ04/VVDjXd2kyVh-W3dRXZL22w= GS9W4nNzqf5K8DygN1HNyZ07lFdnW50l5tj6lZ3pDW695c7S1Lxpz2W5974w22RrrvMW8FzrJG7= mVnf9W8mMNW16f9YtnW3Hy4KJ2hPr6mN8T00gZj1qQWW3rm1kN5kp-GcW1bnJcp2KwvzpW1T1-b= X8K7MVbW8DBCsV3p8jkHW48kJk_5zFRrcW3zF6fg52T1YQW6nYkmb15XY8MN3GDBy5sD7wJW1wK= BkX5TqbJ5W6C1znS8LCXspW2Y4-nb6xjcfPW3Dxy2N6F_HvqW6Wg2HS46jjWmW5yfrzp4mtYjvN= 4Y1JWXwTy1bW4S5fwH3LdFVCW1Vyf8z7DZ2rSW6SlKFs4Xx56QW5Pn7SL86DvG3W20T8Z47jzgC= BW6ZwtVR58M1MgW6qLyck64fZVGN4K3DjwtflQ6W1Pw3N36_5t-WW6tz5dv3vjwYKN8_tFpbVPx= PQW4-6qkK2HSPM_W7vGBbb89Q0G9Vfd8nc6XTgrhW7TbYxk3RFH5BW7VstKl1D7XvPV6yCN38vG= L7DVq-r7P2Tzl2qW8LkSvq5yk6kcW2rRZBX30CYvvW1V50J32ZT641W1l_KCZ2TFTl5W5_vvg86= jgH6KW2GDg6z6m6fBcW26XDz45mSjTyW4m0Hd_7c8NtDW8N58Gr3L1trHdNCbGK04 ..) and p= rovides the full experimental detail. The data shows that this approach: =F0=9F=AB=A7 Delivers higher T cell recovery =F0=9F=AB=A7 Supports robust expansion and favorable phenotype =F0=9F=AB=A7 Shows increased cytotoxicity =F0=9F=AB=A7 Maintains comparable CD3+ purity All results were generated within a single, closed Sepax workflow and bench= marked against an in-bag CD4/CD8 positive selection method. Download the App Note (https://cDHpZ04.na1.hubspotlinks.com/Ctc/T+113/cDHpZ04/VVDjXd2kyVh-W3dRXZL= 22wGS9W4nNzqf5K8DygN1HNy-v3pyd0W7Y8-PT6lZ3mjW1gv4jB1hbD34W8mCtCX6bpf0FW64ws= dm7mQP7dW1bZkJ-4W-4C8W3_dWcF5Tjby_W5t_DTY3TLyDcW1Dg7Vj26TzjdVmJVys5r-RFWW2N= SKjC1c-fLxW14Fj_M7pmpYSN7l9ZyVKYlVnW4fBfdT4KbQZBW1VncWr3yBDttV48Km74zQ4fFW5= 7td5s2q4nN_W5MNKCM8PPJn3W3RFKrX6Jbn4zW7Xpvt12Q0CVPW7qjTN99cKbgTMv43RySX4nDW= 8z64gJ9fxL30W30qNm13jryGPW8wFJnW7GrvmdW74SPpk4Y-ZgRW5SJm8M26V-l1W3lYNcd3TT1= 9Pf3yjyn404 ) If you have questions after reviewing the data or would like to discuss how= this workflow could fit into your process, feel free to reach out here (ht= tps://cDHpZ04.na1.hubspotlinks.com/Ctc/T+113/cDHpZ04/VVDjXd2kyVh-W3dRXZL22w= GS9W4nNzqf5K8DygN1HNyZW3pyd0W6N1vHY6lZ3mqW2pzwWc8k1tQMW7GpFCF3GbnSgW4qhyQM6= JSC33W9jt3_f20dtsVVtbSxn2TSpCKW3XtVFC4Vh0YpW97GkLp5r6tkyW2bx6p14BwnCdW1hv_N= r3qLhSgW5WqTrf5syD4QW54zTNl2ZlRxBW4M67jg4ZgbWHW78F-_m34X5xqW6XYST05MQGYZW7Z= YmqX9fJ7cjVN2VmK541WPGW4r8b0b3HcH7sTsb2V2QNpr5W9dmJPM4qQVFbW5dQ5dN1xQ_HdW5c= Rswv8xKkV8W4Mh1K95xwK36f5GPnyl04 ) or reply to this email. Akadeum Life Sciences=C2=AE, 674 S Wagner Rd, Ann Arbor, MI 48103, 734-707-= 1233 Unsubscribe (https://hs-5302473.s.hubspotemail.net/hs/preferences-center/en= /direct?data=3DW2nXS-N30h-RjW3BTN-j3_Jp5NW4hs4K33X_DsrW4tkHH521pfRYW2Hp_Z92= MRw7fW4kt5LB1Qnq7YW3g1Jwk1LqXmZW2xyxQb1BlGZdW4fsmh52KxrzYW2WtnyZ4fjr2gW3K3n= NN255MVLW2qVB3z3SSGv9W2pbt8647sXltW3bz08822TgHPW38n5TP2MSNfWW1XtFn52YKv3ZW4= fcrVs45XHBNW1Qj-_Q38b9DRW2MNYJ33_Bb5mW2PnCvK2xtLy6W2zygnM2FKvqmW3P3lQJ2r5BN= hW2p9B1N4fHqskW3C1VHy3XMJQ4W4fN0n82TGZvwW23jRSk1_jq7bW2FBMK73yR2MkW1NFKsX2Y= CbvWW1VkwJl4cGPXHW30vqyM3jqLwWW32rgzf3z0sqTW34wHFl2HZxw8W4mC2YW2KYwQ6W3_F75= d2RxDyJW3BVbgp3R16VsW4pD6Ql2PhBjbW2Rjcsh2MRSzdW3gm3_Y20W_tWW1LgwqD3gdtXfW36= pdbL3NCq9wW2FBmLd23h6MHW4fwFgT2YKY1DW3yMF_x36pH8rW3hZg-H2r1WQ-W3GWp_72WhPZ8= W4fsm6P1QgwyQW3_wsZV4kK0gBW3VZmJX41TKSkW1XryWK1X8V32W3VHQgz2TdFFDW2FTj3L2PV= y0vW3294wC2KJdPRW4t2HK6251CYVW4kgj9W2CNY_dW38dbHT2MByPgW2Ysjfv3_vbzD0&_hsen= c=3Dp2ANqtz-9Nb6_tLxIpdbHFAuBn9Gqa2M-k1_-VAUNX6C-kKtdbSQGKEm7HPXQfY76qXGjN7= HQDeeCy3x9yZAXqiHjkMIzcawkSrg&_hsmi=3D402066878 ) Manage preferences (https://hs-5302473.s.hubspotemail.net/hs/preferences-ce= nter/en/page?data=3DW2nXS-N30h-RjW3BTN-j3_Jp5NW4hs4K33X_DsrW4tkHH521pfRYW2H= p_Z92MRw7fW4kt5LB1Qnq7YW3g1Jwk1LqXmZW2xyxQb1BlGZdW4fsmh52KxrzYW2WtnyZ4fjr2g= W3K3nNN255MVLW2qVB3z3SSGv9W2pbt8647sXltW3bz08822TgHPW38n5TP2MSNfWW1XtFn52YK= v3ZW4fcrVs45XHBNW1Qj-_Q38b9DRW2MNYJ33_Bb5mW2PnCvK2xtLy6W2zygnM2FKvqmW3P3lQJ= 2r5BNhW2p9B1N4fHqskW3C1VHy3XMJQ4W4fN0n82TGZvwW23jRSk1_jq7bW2FBMK73yR2MkW1NF= KsX2YCbvWW1VkwJl4cGPXHW30vqyM3jqLwWW32rgzf3z0sqTW34wHFl2HZxw8W4mC2YW2KYwQ6W= 3_F75d2RxDyJW3BVbgp3R16VsW4pD6Ql2PhBjbW2Rjcsh2MRSzdW3gm3_Y20W_tWW1LgwqD3gdt= XfW36pdbL3NCq9wW2FBmLd23h6MHW4fwFgT2YKY1DW3yMF_x36pH8rW3hZg-H2r1WQ-W3GWp_72= WhPZ8W4fsm6P1QgwyQW3_wsZV4kK0gBW3VZmJX41TKSkW1XryWK1X8V32W3VHQgz2TdFFDW2FTj= 3L2PVy0vW3294wC2KJdPRW4t2HK6251CYVW4kgj9W2CNY_dW38dbHT2MByPgW2Ysjfv3_vbzD0&= _hsenc=3Dp2ANqtz-9Nb6_tLxIpdbHFAuBn9Gqa2M-k1_-VAUNX6C-kKtdbSQGKEm7HPXQfY76q= XGjN7HQDeeCy3x9yZAXqiHjkMIzcawkSrg&_hsmi=3D402066878 ) ------=_Part_1767517_1243901796.1770308112951 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable <= !-- New App Note: Microbubbles Integrate with the Cytiva Sepax=E2=84= =A2 C-Pro Cell Processing System =20 =20 =20 =20 =20 =20 =20 =20
Higher recovery, favorable phenotype, and increased cytotoxic= ity in a closed Sepax workflow
=20
=20 =20
=20
3D"Email

Hi Alvaro,

 

We=E2=80=99ve released a new application note evaluating a fully closed T cell isolation workflow integ= rating Akadeum microbubbles with the Cytiva Sepax=E2=84=A2 C-Pro Cell Proce= ssing System in a CD19 CAR-T model.

 

This application note accompanies the data shared in our recent webinar and provides the full ex= perimental detail.

 

The data shows that this approach:

=F0=9F=AB=A7 Delivers higher T cell recovery

=F0=9F=AB=A7 Supports robust expansion and fav= orable phenotype

=F0=9F=AB=A7 Shows increased cytotoxicity

=F0=9F=AB=A7 Maintains comparable CD3+ purity<= /span>

 

All results were generated within a single, closed Sepax = workflow and benchmarked agains= t an in-bag CD4/CD8 positive selection method.

If you have questions after reviewing the data= or would like to discuss how this workflow could fit into your process, fe= el free to reach out here or reply to t= his email.

3D"logo"
=20
=20 =20
=20

Akadeum Life Sciences=C2=AE, 674 S Wagner Rd, Ann Arbor, MI 48103= , 734-707-1233

Unsubscribe Manage preferences

=20
=20 3D"" ------=_Part_1767517_1243901796.1770308112951--